

Inventor(s): Bjamason

Appln. No.: 10

036,371

Series Code ↑

Serial No. ↑

Filed: January 7, 2002

Hon. Commissioner of Patents
Washington, D.C. 20231

Group Art Unit 1651

Examiner: PATTEN, P. A.

Atty. Dkt. P 284960

176 US1-DIV

M#

Client Ref

Appln. Title: Fish serine proteinases and
their pharmaceutical and
cosmetic use

Sir:

REPLY/AMENDMENT/LETTER

Date: September 6, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☒ NOT made
B. ☐ Withdrawn
C. ☐ made herewith
D. ☐ made previously

For B & C
See **Required
Separate Paper**
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	15	**minus 20	0	x \$18/\$9 = + \$0	103/203
3. Independent Claims	2	***minus 3	0	x \$84/\$42 = + \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) add				+ \$280/\$140 = + \$0	104/204
5. Original due Date: September 6, 2002		<input type="checkbox"/> NONE			
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) \$110/\$55 = (2 mos) \$400/\$200 = (3 mos) \$920/\$460 = (4 mos) \$1,440/\$720 = (5 mos) \$1,960/\$980 =	+ \$0		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8. Extension Fee			+ \$0		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee			+ \$110/\$55 + \$0 148/248		
10. If IDS attached requires Official Fee under Rule 97 (c), add			+ \$180 126		
or if Rule 97(d) Request add			+ \$180 126		
11. After-Final Request Fee per rules 129(a) and 17(r)			+ \$740/370 + \$0 146/246		
12. No. of additional inventions for examination per Rule 129(b)			x \$740/370 ea + \$0 149/249		
13. Request for Continued Examination (RCE)			+ \$740/370 + \$0 1179/1279		
14. Petition fee for			+ \$0		
15. TOTAL FEE =			\$0		
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".					
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.					
18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.					
			PLEASE CHARGE OUR DEP. ACCT		

Our Deposit Account No. 03-3975)

(Our Order No. 81691 284960

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robert W. Hahl

P.O. Box 10500

McLean, VA 22102

Tel: (703) 905-2000

Reg. No. 33893

Fax: (703) 905-2500

Tel: (703) 905-2251

RECEIVED

Atty/Sec: RWH/AMX

NOTE: SEP 11 2002
File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments**TECH CENTER 1600/2900**



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/036,371	01/07/2002	Jon Bragi Bjarnason	P 284960 176US1-DIV	5545

7590 08/06/2002
Pillsbury Winthrop LLP
Intellectual Property Group
1600 Tysons Boulevard
McLean, VA 22102



EXAMINER

PATTEN, PATRICIA A

ART UNIT	PAPER NUMBER
----------	--------------

1651

DATE MAILED: 08/06/2002

4

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED
PILLSBURY WINTHROP LLP/VA

AUG 09 2002

CL 081691 MT# 0284960
ATTY(S) TSB
DUE: SEPT 6, 2002
DKT BY (1) (2) DTH

BEST AVAILABLE COPY



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
10/036,371	1/7/02	Bjarnason, J.	P 284960 167US1-DIV



EXAMINER	
Patten	
ART UNIT	PAPER NUMBER
1651	4

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1), (a)(2), (c) and (e). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicants are **required** to subunit a new paper copy and CRF encompassing all of the sequences, or alternatively to cancel the additional sequence and request transfer of the sequence disclosure from the parent file in response to this Office action for the response to be complete.

The following language is a sample of a paragraph that should be submitted in a separate paper to effect this transfer of the CRF.

The computer readable form in this application, [Serial Number], is identical with that filed in [Serial Number], filed [Date]. In accordance with 37 CFR 1.1821(e), please use the [first-filed, last-filed, or only (whichever is applicable)] computer readable form

BEST AVAILABLE COPY

filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is [included in the originally-filed specification of the instant application, or included in a separately filed preliminary amendment for incorporation into the specification (whichever is applicable)].


APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed to Examiner Patricia Patten Art Unit 1651, whose telephone number is (703) 308-1189.

BEST AVAILABLE COPY



Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

A handwritten signature in black ink, appearing to read "Jon P. Weber", with a large, stylized initial "J" and a checkmark-like flourish at the end.

Jon P. Weber, Ph.D.
Primary Examiner

BEST AVAILABLE COPY

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

BEST AVAILABLE COPY